Envision a world
where no patient
is left behind
Attovia is advancing a new generation of precision biologics for patients with high unmet need across immune-mediated diseases.
While current therapies address parts of the underlying biology, many patients remain undertreated. Our multispecific approach is designed to engage multiple disease pathways—raising the bar for therapeutic performance.
At the core of our strategy is the proprietary ATTOBODY™ platform—a powerful, modular protein design platform to create novel multispecific medicines—overcoming the limitations of existing single-pathway treatments.
We’re driven by one goal: to change what patients can expect from their treatments—and from their futures.
Envision a world
where no patient
is left behind
Attovia is advancing a new generation of precision biologics for patients with high unmet need across immune-mediated diseases.
While current therapies address parts of the underlying biology, many patients remain undertreated. Our multispecific approach is designed to engage multiple disease pathways—raising the bar for therapeutic performance.
At the core of our strategy is the proprietary ATTOBODY™ platform—a powerful, modular protein design platform to create novel multispecific medicines—overcoming the limitations of existing single-pathway treatments.
We’re driven by one goal: to change what patients can expect from their treatments—and from their futures.
Leading the way to breakthrough multispecifics
We are a team of veteran drug development leaders passionate about bringing new and improved medicines to patients.
Tao Fu, MBA, M.S.
Chief Executive Officer
Steven Chan
Chief Financial Officer
Hubert Chen, M.D., M.P.H.
Chief Medical Officer
Zaneta Odrowaz, PhD
Chief Business Officer
Petter Veiby, Ph.D.
Chief Scientific Officer
Hangjun Zhan, Ph.D.
Chief Technology Officer
David Bellovin, Ph.D.
VP, Discovery & Translational Biology
Bora Han, Ph.D.
VP, Head of Preclinical Development
Veit Schmelmer, Ph.D.
VP, Project Management & Portfolio Strategy
Tao Fu, MBA, M.S.
Chief Executive Officer
Steven Chan
Chief Financial Officer
Hubert Chen, M.D., M.P.H.
Chief Medical Officer
Zaneta Odrowaz, PhD
Chief Business Officer
Petter Veiby, Ph.D.
Chief Scientific Officer
Hangjun Zhan, Ph.D.
Chief Technology Officer
David Bellovin, Ph.D.
VP, Discovery & Translational Biology
Bora Han, Ph.D.
VP, Head of Preclinical Development
Veit Schmelmer, Ph.D.
VP, Project Management & Portfolio Strategy
Hubert Chen, M.D., M.P.H.
Hangjun Zhan, Ph.D.
David Bellovin, Ph.D.
